Literature DB >> 12655317

Neurotrophic effects of electroconvulsive therapy: a proton magnetic resonance study of the left amygdalar region in patients with treatment-resistant depression.

Nikolaus Michael1, Andreas Erfurth, Patricia Ohrmann, Volker Arolt, Walter Heindel, Bettina Pfleiderer.   

Abstract

Negatively balanced neurotrophic factors may be important in precipitating clinical depression. Recently, it has been reported that antidepressant therapy may exert positive neurotrophic effects. The aim of this study was to detect probable neurotrophic changes during electroconvulsive therapy (ECT). For this purpose, N-acetylaspartate (NAA), an amino acid exclusively located in neurons, and other brain metabolites such as glutamine/glutamate (Glx), choline (Cho), and creatine (Cr) were measured in patients by localized proton magnetic resonance spectroscopy. A total of 28 severely depressed patients (DSM-IV) were enrolled, and the left amygdalar region was investigated by proton STEAM spectroscopy before and after unilateral ECT. The results were compared with 28 age- and gender-matched controls using nonparametric paired and unpaired tests. A significant increase in NAA was observed only in ECT responders (n=14; p=0.019). Five out of 14 nonresponders to ECT monotherapy were remeasured following a clinical improvement after continued ECT combined with antidepressants and were then found also to present a significant increase in NAA. In all successfully treated patients, parallel observations, that is, increased levels, were made for Glx, whereas Cho and Cr were unchanged. In conclusion, our preliminary finding of increased NAA concentrations after successful ECT may indicate a probable neurotrophic effect of ECT.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12655317     DOI: 10.1038/sj.npp.1300085

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  43 in total

Review 1.  [Value of diagnostic imaging in evaluation of electroconvulsive therapy].

Authors:  T Frodl; E M Meisenzahl; H-J Möller
Journal:  Nervenarzt       Date:  2004-03       Impact factor: 1.214

Review 2.  Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders.

Authors:  Cagri Yüksel; Dost Öngür
Journal:  Biol Psychiatry       Date:  2010-08-21       Impact factor: 13.382

3.  Co-localization of corticotropin-releasing factor and vesicular glutamate transporters within axon terminals of the rat dorsal raphe nucleus.

Authors:  Maria Waselus; Elisabeth J Van Bockstaele
Journal:  Brain Res       Date:  2007-08-14       Impact factor: 3.252

Review 4.  Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.

Authors:  Gerard Sanacora; Giulia Treccani; Maurizio Popoli
Journal:  Neuropharmacology       Date:  2011-08-03       Impact factor: 5.250

5.  Examining SLV-323, a novel NK1 receptor antagonist, in a chronic psychosocial stress model for depression.

Authors:  Boldizsár Czéh; Olga Pudovkina; Marieke G C van der Hart; Mária Simon; Urs Heilbronner; Thomas Michaelis; Takashi Watanabe; Jens Frahm; Eberhard Fuchs
Journal:  Psychopharmacology (Berl)       Date:  2005-02-22       Impact factor: 4.530

6.  Biochemical abnormalities of the medial temporal lobe and medial prefrontal cortex in late-life depression.

Authors:  Talaignair N Venkatraman; Ranga R Krishnan; David C Steffens; Allen W Song; Warren D Taylor
Journal:  Psychiatry Res       Date:  2009-04-30       Impact factor: 3.222

7.  Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression.

Authors:  Anteneh M Feyissa; Agata Chandran; Craig A Stockmeier; Beata Karolewicz
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-10-25       Impact factor: 5.067

8.  Hippocampal abnormalities of glutamate/glutamine, N-acetylaspartate and choline in patients with depression are related to past illness burden.

Authors:  Javier de Diego-Adeliño; Maria J Portella; Beatriz Gómez-Ansón; Olga López-Moruelo; Maria Serra-Blasco; Yolanda Vives; Dolors Puigdemont; Rosario Pérez-Egea; Enric Álvarez; Víctor Pérez
Journal:  J Psychiatry Neurosci       Date:  2013-03       Impact factor: 6.186

9.  Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression.

Authors:  R Bernard; I A Kerman; R C Thompson; E G Jones; W E Bunney; J D Barchas; A F Schatzberg; R M Myers; H Akil; S J Watson
Journal:  Mol Psychiatry       Date:  2010-04-13       Impact factor: 15.992

Review 10.  Biological substrates underpinning diagnosis of major depression.

Authors:  Etienne Sibille; Beverly French
Journal:  Int J Neuropsychopharmacol       Date:  2013-05-14       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.